883989-27-3

Upstream product

• 51699-45-7 (S)-(-)-1-(3'-Chlorophenyl)-1,3-Propanediol 
• 777-52-6 1-dichlorophosphoryloxy-4-nitro-benzene 
• 625095-57-0 (S)-(-)-1-(3-Chlorophenyl)-1,3-propanediol 
• 805235-83-0 (4R)-(+)-trans-2-(4-nitrophenoxy)-2-oxo-4-(3-chlorophenyl)-1,3,2-dioxaphosphorinane 
• 33167-21-4 3-(3-chloro-phenyl)-3-oxo-propionic acid ethyl ester 
• 100-02-7 4-nitro-phenol 
• 893643-63-5 2-(3-chloro-benzoyl)-3-oxo-butyric acid ethyl ester 
• 618-46-2 m-Chlorobenzoyl chloride 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome P450-activated prodrugs

Four novel cyclic phosphates of the anti-inflammatory agent 5-aminosalicylic acid (5-ASA) were designed and synthesized as cytochrome P450 (CYP)-activated prodrugs. These prodrugs can be used for targeting into gut wall, since these types of cyclic phosph

Phosphoryl N - fatty acyl nucleoside analogues for treatment of viral hepatitis and liver cancer

The invention discloses a phosphoryl N-fatty acyl nucleoside analogue for treating viral hepatitis and liver cancer. The phosphoryl N-fatty acyl nucleoside analogue is characterized in that a nucleoside analogue is modified by a cyclophosphoryl group and

NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES

Novel 2'-C-methyl nucleoside 5 '-monophosphate and 4'-C-methyl nucleoside 5'- monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral inf

Novel 2'-C-methyl nucleoside derivatives

Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described: